Premium
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin
Author(s) -
Jabbour Elias,
Advani Anjali S.,
Stelljes Matthias,
Stock Wendy,
Liedtke Michaela,
Gökbuget Nicola,
Martinelli Giovanni,
O'Brien Susan,
White Jane Liang,
Wang Tao,
Luisa Paccagnella M.,
Sleight Barbara,
Vandendries Erik,
DeAngelo Daniel J.,
Kantarjian Hagop M.
Publication year - 2019
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25394
Subject(s) - medicine , calicheamicin , hazard ratio , minimal residual disease , cytogenetics , oncology , leukemia , gastroenterology , biology , confidence interval , genetics , chromosome , myeloid leukemia , gene
Karyotype is frequently used to predict response and outcome in leukemia. This post hoc exploratory analysis evaluated the relationship between baseline cytogenetics and outcome in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with inotuzumab ozogamicin (InO), a humanized CD22 antibody conjugated to calicheamicin, in the phase 3, open‐label, randomized INO‐VATE trial. Data as of March 8, 2016, are presented in this analysis. Of the 326 patients randomized, 284 had screening karyotyping data (144 in the InO arm and 140 in the standard care [SC] arm). With InO, complete remission or complete remission with incomplete hematologic recovery (CR/CRi), minimal residual disease negativity rates, and overall survival (OS) were not significantly different between cytogenetic subgroups. CR/CRi rates favored InO over SC in the diploid with ≥20 metaphases, complex, and “other” cytogenetic subgroups. The OS hazard ratio favored InO over SC in the diploid with ≥20 metaphases, complex, and other cytogenetic subgroups. Generally, InO is effective and provides substantial clinical benefit in patients with R/R ALL who have specific baseline karyotypes.